drugset
drugset / Trial / NCT06181045

A Study of LY3410738 in Healthy Adult Participants

NCT06181045 ↗

Phase 1 Completed 42 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to assess the safety and tolerability of LY3410738 and to look at the amount of the study drug, LY3410738, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the total duration of the study will be 53 days, including screening.

Timeline

Start
2021-02-24
Primary completion
2021-08-04
Completion
2021-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CRELOSIDENIB Small molecule — Oral

Indications

No indication recorded.